Company news

Marker Therapeutics, Inc. news in 2021

Marker Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors

December 8, 2021

Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting

November 17, 2021

Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results

November 9, 2021

Marker Therapeutics to Present at Three Upcoming September Investor Conferences

September 6, 2021

Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas

August 18, 2021

Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results

August 9, 2021

Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility

July 27, 2021

Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML

July 5, 2021

Marker Therapeutics to Present at the Virtual Raymond James Human Health Innovation Conference

June 15, 2021

Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results

May 11, 2021

Marker Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast on Wednesday, May 12, 2021

April 28, 2021

Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at the 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

April 26, 2021

Marker Therapeutics, Inc. Announces Closing of Public Offering of Common Stock

March 15, 2021

Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference

March 14, 2021

Marker Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock

March 11, 2021

Marker Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

March 10, 2021

Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results

March 8, 2021

Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplant

March 2, 2021

Marker Therapeutics Announces Completion of New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates

January 12, 2021

Marker Therapeutics Announces FDA Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial

January 4, 2021

Decks in 2021